MIRM vs MRK
Mirum Pharmaceuticals, Inc. vs Merck & Co. — AI-powered side-by-side comparison
MIRM
Mirum Pharmaceuticals, Inc.
56
Watch
VS
| Metric | MIRM | MRK |
|---|
| AI Score |
56
|
70
|
| Price |
$98.27
|
$130.34
|
| P/E Ratio |
-6.75×
|
103.53×
|
| ROE |
-7.4%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
81.7%
|
75.4%
|
| Debt / Equity |
-72.97×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
33.9
|
64.5
|
| Beta |
0.507
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MIRM versus MRK.
MRK leads by 14 points.
MRK scores 70/100 (Buy) versus MIRM at 56/100 (Watch).
MIRM Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 44.0% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 13.0x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 44.0% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 13.0x prices in significant intangible value — Value
- ROE of only -289.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical